Paratek Pharmaceuticals

Paratek Pharmaceuticals is a mission-driven, commercial-stage biopharma focused on creating 'Positive Patient Stories®' by tackling serious infectious diseases and chronic inflammatory conditions. The company has successfully transitioned from R&D to a fully integrated commercial entity with two marketed products: NUZYRA® (omadacycline), a modern tetracycline antibiotic, and XHANCE® (fluticasone propionate), a novel-delivery nasal spray. Its strategy leverages deep expertise in tetracycline chemistry and targeted drug delivery to serve substantial specialty markets while addressing critical public health threats like antimicrobial resistance.

Paratek's core technology involves modernizing tetracycline-class chemistry to overcome antibiotic resistance and developing the proprietary Exhalation Delivery System (EDS) to target drug delivery deep into the sinonasal cavities.